Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, PK, and Efficacy of Intravenous Administration of HY1272 in Patients With Late Phase Solid Tumors or EGFRm+NSCLC

NCT06218940 is registered in ClinicalTrials.gov with Newsoara Biopharma Co., Ltd. as lead sponsor.

NCT NCT06218940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06218940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Multicenter Study to Evaluate Safety, Tolerability, PK, and Efficacy of Intravenous Administration of HY1272 in Patients With Late Phase Solid Tumors or EGFRm+NSCLC
Lead sponsor
Newsoara Biopharma Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 1, 2024
Completion date
December 1, 2027
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv